US45254U1016 - ADR
IMMURON LTD-SPON ADR
NASDAQ:IMRN (12/30/2024, 12:18:06 PM)
1.91
+0.01 (+0.53%)
Immuron Ltd. is a biopharmaceutical company, which focuses on the development and commercialization of a novel class of specifically targeted polyclonal antibodies. The company is headquartered in Melbourne, Victoria. The company operates through two segments: Research and development (R&D), and Hyperimmune products. The R&D segment is focused on R&D projects performed in Australia and the United States. Hyperimmune products segment is engaged in Travelan and Protectyn activities which occur predominantly in Australia, the United States and Canada. Its flagship products consist of Travelan and Protectyn. Travelan is an orally administered passive immunotherapy that prophylactically reduces the likelihood of contracting traveler’s diarrhea and is sold in pharmacies throughout Australia. Protectyn is sold online and in health practitioner clinics and is marketed as an immune supplement to help maintain a healthy digestive function and liver. Its clinical programs include Travelan (IMM-124E), IMM-529, and CampETEC.
IMMURON LTD-SPON ADR
L 3 62 Lygon St
Melbourne VICTORIA 3053
P: 61398245254
CEO: Jerry Kanellos
Employees: 7
Website: https://www.immuron.com.au
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com
MELBOURNE, Australia, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN) is pleased to advise our Chief Executive Officer, Steven...
Here you can normally see the latest stock twits on IMRN, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: